Forbius completes enrollment into phase 1a solid tumour trial of AVID200

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced that the Phase 1a solid tumor trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, administered as a monotherapy has fully enrolled.